Zavegepant
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2023
- First approval year
- 2023
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Zavegepant
- Molecular weight
- 638.82
- Structure (SMILES)
- Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12
- bhv 3500
- BHV-3500
- bms 742413
- bms 742413 01
- BMS-742413
- BMS-742413-01
- vazegepant
- Vazegepant
- zavegepant
- Zavegepant
- zavegepant [INN]
- ZAVEGEPANT [USAN]
- Zavegepant [WHO-DD]
- zavegepant inn
- zavegepant usan
- zavegepant who dd
- ATC classification codes
- N02CD08
Sources for recorded values
- CAS registry numbers
- 1337918-83-8
- ChEMBL ID
- CHEMBL2397415
- InChIKey
- JJVAPHYEOZSKJZ-JGCGQSQUSA-N
- PubChem compound IDs
- 53472683
- RxNorm IDs (RxCUI)
- 2637955
- FDA ingredient codes (UNII)
- ODU3ZAZ94J
- Applicant
- PFIZER
- Approval date
- 9 Mar 2023
- Application number
- NDA216386
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- zavegepant
- Type
- Synthetic organic
- Drug name stem
- -gepant
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- RAMP1
- Protein identifier
- O60894
- Median affinity
- 10.66
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- RAMP1
- Protein identifier
- O60894
- Median affinity
- 10.64
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- CALCRL
- Protein identifier
- Q16602
- Median affinity
- 10.66
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- CALCRL
- Protein identifier
- Q16602
- Median affinity
- 10.64
- Affinity units
- pKi
- Mechanism
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist
- Action type
- Antagonist
- Target
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1
- Protein identifier
- O60894
- Mechanism
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist
- Action type
- Antagonist
- Target
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1
- Protein identifier
- Q16602
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
- Mechanism
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist
- Action type
- Antagonist
- Target
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1
- Condition
- Asthma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Migraine Disorders
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005277
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- NCT03872453
- NCT04408794
- NCT04571060
- NCT04804033
- NCT05989048
- NCT04346615
- NCT04987944
- Dose
- 10mg
- Route
- Intranasal
- How often
- As needed
Conditions of use
- Maximum 10mg per 24 hours
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 120.67
- Calculated partition coefficient (ALogP)
- 3.45
- Calculated partition coefficient (XLogP)
- 3.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 6
- Heavy atoms
- 47
- Molecular formula
- C36H46N8O3
- Monoisotopic mass
- 638.36928736
- Natural product
- No
- Recorded assays
- 50
- Active assays
- 6
Active assay types
- Confirmatory
- Calcitonin Gene-Related Peptide Receptor Antagonists
Pharmacologic agents that block NOCICEPTIVE PAIN signaling from CALCITONIN GENE-RELATED PEPTIDE RECEPTORS. They may be useful for the treatment of pain associated with MIGRAINE DISORDERS and OSTEOARTHRITIS.
These details could not be displayed.
Related records
Trials (17)
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
- A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
- A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
- A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
- A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
- A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
- A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
- A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women
- Acute Migraine Treatment in the ED With Gepants
- Acute Treatment Trial in Adult Subjects With Migraines
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
- Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
- Randomized Trial in Adult Participants With Acute Migraines
- Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma
- Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
- Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache
In development for (3)
- Asthma Phase 1
- COVID-19 Phase 2
- Migraine disorder Phase 3